Concepedia

Author

Devi SenGupta

Gilead Sciences (United States)ORCID

Also Known As

Carter, C., D N SENGUPTA, D N Sengupta, D SenGupta, D Sengupta, D. N. Sengupta, D. SenGupta, D. Sengupta, D.N. Sengupta, Debarshee Sengupta

89

Publications

5.5K

Citations

28

H-Index

41

Concepts

All Affiliations

Gilead Sciences (United States)University of California, San FranciscoOrlando Immunology CenterHospital Universitario La PazGeorge Washington University
DS

About

Devi SenGupta is an author at Gilead Sciences (United States) specializing in medicine, hiv, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

11

804

2

Public Health

1

1

41

3

Allergy

1

1

16

4

Cell Biology

1

1

38

5

Epidemiology

1

1

41

Devi SenGupta

×

32

Publications

4.9K

Citations

26

H-Index

YearCitations

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Jason D. Goldman, David Chien Lye, David S.C. Hui,

New England Journal of Medicine

2020

1.4K

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

Christoph D. Spinner, Robert Gottlieb, Gerard J. Criner,

JAMA

2020

1.3K

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Paul E. Sax, Anton Pozniak, Marisa Montes,

The Lancet

2017

385

Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities

Nicole Frahm, Bette Korber, Craig Adams,

Journal of Virology

2004

274

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment

Anton Pozniak, José Ramón Arribas, Joseph Gathe,

JAIDS Journal of Acquired Immune Deficiency Syndromes

2015

184

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate

Samir K. Gupta, Frank A. Post, José Ramón Arribas,

AIDS

2019

155

HERV-K–specific T cells eliminate diverse HIV-1/2 and SIV primary isolates

R. Brad Jones, Keith Garrison, Shariq Mujib,

Journal of Clinical Investigation

2012

94

Heat Shock Protein-Mediated Cross-Presentation of Exogenous HIV Antigen on HLA Class I and Class II

Devi SenGupta, Philip J. Norris, Todd J. Suscovich,

The Journal of Immunology

2004

84

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

Chloe Orkin, Edwin DeJesus, Moti Ramgopal,

The Lancet HIV

2017

75

Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus–1

Sharon A. Riddler, Michael F. Para, Constance A. Benson,

Clinical Infectious Diseases

2020

72

Page 1